LBL-054-CD3 / Leads Biolabs - LARVOL DELTA

LBL-054-CD3: An anti-CDH17 and CD3 bispecific antibody for the treatment of CDH17-positive gastrointestinal cancer (AACR 2025) - "The study demonstrates that LBL-054-CD3 has potent binding affinity to the membrane-proximal region of CDH17 and mediates T-cell cytotoxicity against various levels of CDH17 expressing tumor cells. Further, the bispecific antibody is shown excellent antitumor activity in both in vitro and in vivo experiments."

IO biomarker • Gastrointestinal Cancer • Oncology • Solid Tumor • CDH17